AS01<sub>B</sub>-, MF59-, and alum-based adjuvants and HIV vaccine immunogenicity: a <i>post-hoc</i> cross-protocol comparison of results from HVTN 100, 107, 120, and 702.

Front Immunol · 2026 · PMC13017943 · PMID 41909709

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

did not reach statistical significanceno p-value reported

showed a trendno p-value reported

AS01 B also showed a trend toward greater reactogenicity, though this difference did not reach statistical significance.

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.

AS01&lt;sub&gt;B&lt;/sub&gt;-, MF59-, and alum-based adjuvants and HIV vaccine immunogenicity: a &lt;i&gt;post-hoc&lt;/i&gt; cross-protocol comparison of results from HVTN 100, 107, 120, and 702.

The sentences

AS01<sub>B</sub>-, MF59-, and alum-based adjuvants and HIV vaccine immunogenicity: a <i>post-hoc</i> cross-protocol comparison of results from HVTN 100, 107, 120, and 702.